SCHEMBL26407117

SCHEMBL26407117

CC(C)C(=O)NCCCCOCCCCS

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.37
▸ ALDH1A2 O94788 1/20 0.37
▸ ALDH2 P05091 1/20 0.37
▸ ALDH1A3 P47895 1/20 0.37
▸ EPHX2 P34913 5/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ HDAC3 O15379 4/20 0.36
▸ HDAC1 Q13547 4/20 0.36
▸ HDAC6 Q9UBN7 4/20 0.36
▸ HDAC2 Q92769 3/20 0.36
▸ HDAC4 P56524 2/20 0.36
▸ HDAC7 Q8WUI4 2/20 0.36
▸ HDAC10 Q969S8 2/20 0.36
▸ HDAC11 Q96DB2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22799828 0.84 DPP7 (0.50) KMT2AMEN1EPHX2MAPTHSD17B10
SCHEMBL13668152 0.83 KMT2A (0.57) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL25914484 0.83 KMT2A (0.42) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL23807034 0.83 EPHX1 (0.50) EPHX2TSHRDPP7
SCHEMBL21105998 0.83 KMT2A (0.44) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL25542425 0.83 KMT2A (0.44) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL10141271 0.82 TSHR (0.51) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL22794783 0.81 MMP8 (0.49) KMT2AMEN1MAPTDPP7
SCHEMBL21107013 0.81 MMP8 (0.49) KMT2AMEN1MAPTDPP7
SCHEMBL27268363 0.81 KMT2A (0.47) KMT2AMEN1CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885CYP2D6 3599/4885
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885CYP2D6 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback